A-type lamin-linked lipodystrophies.

Area of Science:

• Genetics
• Endocrinology
• Metabolic Diseases

Background:

• Lipodystrophies are rare genetic disorders characterized by abnormal body fat distribution.
• These conditions are associated with significant metabolic complications, including insulin resistance, dyslipidemia, and diabetes.
• Partial lipodystrophies include Dunnigan syndrome (FPLD) linked to LMNA mutations and PPARgamma-linked forms, both inherited in a dominant pattern.

Purpose of the Study:

• To detail the clinical and genetic characteristics of familial partial lipodystrophy (FPLD).
• To explore the spectrum of phenotypes associated with LMNA gene mutations in lipodystrophy.
• To highlight the metabolic and physical manifestations of these genetic conditions.

Main Methods:

• Review of genetic and clinical data from patients with lipodystrophy.
• Focus on mutations within the LMNA gene, particularly in the C-terminal domain.
• Analysis of associated symptoms including muscular hypertrophy, hyperandrogenism, and metabolic derangements.

Main Results:

• LMNA mutations, predominantly heterozygous substitutions at position 482 (R482W/Q/L), are a major cause of Dunnigan syndrome.
• FPLD presents with lipoatrophy, metabolic syndrome, and sometimes muscular dystrophy-like signs.
• Other LMNA mutations (e.g., R28W, R133L) are associated with varied lipodystrophy and myopathy phenotypes.

Conclusions:

• LMNA gene mutations are central to the pathogenesis of Dunnigan syndrome and related lipodystrophies.
• Lipodystrophies exhibit a wide range of clinical presentations, from metabolic disturbances to muscular abnormalities.
• Understanding the genetic basis of lipodystrophy is crucial for diagnosis and management.